10.21.13
The Aenova Group is continuing its successful period of growth. As the company previously announced, it has found in Haupt Pharma, a company specializing in contract development and manufacturing for the pharmaceutical industry, a partner that will help Aenova achieve a strategic expansion of its portfolio.
Almost a year after the successful takeover of the Temmler Group, the Aenova Group is increasing its annual turnover by around 60% to nearly $1 billion. The agreement has now been signed, but the purchase price remains confidential. The transaction will go ahead subject to the approval of the relevant competition authorities, but is expected to become legally binding at the end of 2013.
Aenova and Haupt Pharma both have global footprints with strong European foundations and headquarters in Germany. “The strategic activities of both companies complement each other very well and this move gives us further areas of expertise strongly focusing on forward-looking sectors in the pharmaceutical market, which are a perfect fit with our existing portfolio,” said Heiner Hoppmann, CEO of the Aenova Group, commenting on the successful partnership.
The merger will add areas such as sterile manufacturing and the production of special active ingredients (including hormones, antibiotics and cytostatics) for the pharmaceutical industry to Aenova’s existing range of solid, semi-solid and liquid dosage forms. The company’s full service portfolio in the future will include all the product groups and all the main dosage forms for medicines and dietary supplements.
These new areas of expertise and the expansion of its range of products and services will strengthen the Aenova Group’s market position in the global market, according to the company. The Aenova Group’s existing production network will increase from eight to 21 sites. In addition to new production facilities in Germany (Berlin, Brackenheim, Münster, Gronau, Regensburg, Wolfratshausen) and in Europe, Aenova will also acquire its first site in Asia (Japan). The number of employees will increase from 2,500 to more than 4,000.
The merger of the two companies also offers the ideal opportunity for Haupt Pharma to consolidate and continue the growth that it has experienced over recent years. Otto Prange, chairman of the supervisory board of Haupt Pharma, will continue to accompany the enterprise in the future as co-shareholder of the Aenova Group. As he explained: “The merger will increase our competitiveness in a challenging market and, as a result, make us significantly more attractive to our customers.”
Almost a year after the successful takeover of the Temmler Group, the Aenova Group is increasing its annual turnover by around 60% to nearly $1 billion. The agreement has now been signed, but the purchase price remains confidential. The transaction will go ahead subject to the approval of the relevant competition authorities, but is expected to become legally binding at the end of 2013.
Aenova and Haupt Pharma both have global footprints with strong European foundations and headquarters in Germany. “The strategic activities of both companies complement each other very well and this move gives us further areas of expertise strongly focusing on forward-looking sectors in the pharmaceutical market, which are a perfect fit with our existing portfolio,” said Heiner Hoppmann, CEO of the Aenova Group, commenting on the successful partnership.
The merger will add areas such as sterile manufacturing and the production of special active ingredients (including hormones, antibiotics and cytostatics) for the pharmaceutical industry to Aenova’s existing range of solid, semi-solid and liquid dosage forms. The company’s full service portfolio in the future will include all the product groups and all the main dosage forms for medicines and dietary supplements.
These new areas of expertise and the expansion of its range of products and services will strengthen the Aenova Group’s market position in the global market, according to the company. The Aenova Group’s existing production network will increase from eight to 21 sites. In addition to new production facilities in Germany (Berlin, Brackenheim, Münster, Gronau, Regensburg, Wolfratshausen) and in Europe, Aenova will also acquire its first site in Asia (Japan). The number of employees will increase from 2,500 to more than 4,000.
The merger of the two companies also offers the ideal opportunity for Haupt Pharma to consolidate and continue the growth that it has experienced over recent years. Otto Prange, chairman of the supervisory board of Haupt Pharma, will continue to accompany the enterprise in the future as co-shareholder of the Aenova Group. As he explained: “The merger will increase our competitiveness in a challenging market and, as a result, make us significantly more attractive to our customers.”
